The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?
After six weeks on a ventilator, she was dying of COVID-19. But doctors took a gamble and gave Mayra Ramirez a double lung transplant. Now she shares what it's like to come back from the brink.
Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower.
Adjuvants play a crucial role in many vaccines' effectiveness. Some scientists say there needs to be more research into developing a wider variety of adjuvants because of how important they are.
For many cancer patients, daily life can feel full of risky choices involving work, family, friends and money. Nearly every option pits the risks of catching the coronavirus against other downsides.
The National Institutes of Health is giving $248.7 million dollars to seven companies developing new technologies for testing, including use of the revolutionary gene-editing technique CRISPR.
Scientists are now checking to see if purified blood serum from people who have recovered from COVID-19 might be more than a useful treatment. Perhaps it's a way to prevent disease in someone else.
Two new human studies back earlier hints that vaccines designed to prevent respiratory infections might also provide some protection against Alzheimer's disease.
Gene therapy has helped a 9-year-old boy regain enough muscle strength to run. If successful in others, the treatment could change the lives of thousands of children with Duchenne muscular dystrophy.
Recent studies have raised fears that immunity to the coronavirus might be fleeting, thus making potential vaccines ineffective. The reality of the science is more complex — and more reassuring.
The first gene therapy for hemophilia could be approved by the FDA within six months, according to the drugmaker, raising hopes among families. But the drug's price could be $3 million per patient.
Faced with a glut of pandemic research from around the world, scientists are confronting their biases and learning to engage with science conducted at institutions they're unfamiliar with.
When scientists revved up the production of an enzyme called GPLD1 in older mice, it stimulated nerve growth in their brains and the animals navigated a maze better.
